Lexicon Pharmaceuticals NASDAQ: LXRX expects first-quarter results next year from a late-stage study of sotagliflozin in hypertrophic cardiomyopathy, while preparing to resubmit the drug for type 1 diabetes in the first quarter of 2027, company executives said at a Jefferies healthcare conference.
THE WOODLANDS, Texas, Nov. 11, 2026 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX), a leading cardiometabolic biopharmaceutical company, today announced that Company management will participate in a fireside chat at the 2026 Jefferies Global Healthcare Conference on Wednesday, November 18, 2026, at 8:00 a.m. GMT in London.
-- In a randomized crossover study, sotagliflozin significantly reduced ex vivo thrombus formation from baseline under both arterial and venous flow conditions -- -- Study in living human heart tissue indicate sotagliflozin acutely and directly reduces myocardial work in hypertrophic cardiomyopathy (HCM) -- -- Findings add mechanistic insight into sotagliflozin's dual SGLT1/SGLT2 inhibition ahead of SONATA-HCM topline results in Q1 2027 -- THE WOODLANDS, Texas, Nov. 09, 2026 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX), a leading cardiometabolic biopharmaceutical company, today announced new data highlighting the cardiovascular effects of its dual SGLT1/2 inhibitor, sotagliflozin, which were shared in two poster presentations at the American Heart Association (AHA) Scientific Sessions 2026. The investigator-initiated studies were sponsored by Lexicon and conducted by investigators at the Ichan School of Medicine at Mount Sinai and Penn Cardiovascular Institute.
Lexicon Pharmaceuticals, Inc. ( LXRX ) Q3 2026 Earnings Call November 5, 2026 8:30 AM EST Company Participants Lisa DeFrancesco - Senior Vice President of Investor Relations & Corporate Communications Michael Exton - CEO & Director Craig Granowitz - Senior VP & Chief Medical Officer Scott Coiante - Senior VP & CFO Conference Call Participants Steven Seedhouse - Cantor Fitzgerald & Co., Research Division Joseph Pantginis - H.C. Wainwright & Co, LLC, Research Division Yigal Nochomovitz - Citigroup Inc., Research Division Lin Tsai - Jefferies LLC, Research Division Presentation Operator Welcome to the Lexicon Pharmaceuticals Third Quarter 2026 Financial Results Conference Call.
Lexicon Pharmaceuticals NASDAQ: LXRX expects two key milestones in the first quarter of 2027: results from a pivotal heart disease trial and a resubmission of its application for a type 1 diabetes treatment, executives said on the company's third-quarter earnings call.
Lexicon Pharmaceuticals (LXRX) came out with a quarterly loss of $0.03 per share versus the Zacks Consensus Estimate of a loss of $0.06. This compares to a loss of $0.04 per share a year ago.
Phase 3 SONATA-HCM study substantially overenrolled; top-line data expected Q1 2027 Positive STENO1 safety data strengthens benefit-risk profile for ZYNQUISTA® NDA resubmission Phase 1 clinical development of LX9851 ongoing by Novo Conference call and webcast at 8:30 am ET THE WOODLANDS, Texas, Nov. 05, 2026 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX), a leading cardiometabolic biopharmaceutical company, today reported financial results for the three months ended September 30, 2026, and provided an update on key corporate milestones and accomplishments. “This quarter brought Lexicon into sharper focus as a cardiometabolic company and has positioned us to approach 2027 with strong momentum and multiple near-term potential catalysts and paths to value creation,” said Mike Exton, Ph.D.
THE WOODLANDS, Texas, Oct. 29, 2026 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX), a leading cardiometabolic biopharmaceutical company, today announced the Company will release its third quarter 2026 financial results on Thursday, November 5, 2026, prior to market open. Management will conduct a conference call and live webcast at 8:30 a.m. ET (7:30 a.m. CT) that day to discuss the financial results and to provide a business update.
-- Patient demographics consistent with prior studies of other agents in HCM and reflect real-world clinical practice -- -- Mean baseline KCCQ-CSS of 59 shows considerable symptom burden at study entry –
-- Preclinical study demonstrates positive effects of sotagliflozin on cardiac function and structure in hypertrophic cardiomyopathy -- -- Second preclinical study shows inhibitory effects of sotagliflozin on platelet activity and thrombus formation -- -- Findings underscore differentiated biology associated with dual SGLT1 and SGLT 2 inhibition -- THE WOODLANDS, Texas, Oct. 21, 2026 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX), a leading cardiometabolic biopharmaceutical company, today highlighted findings from two newly reported preclinical studies that provide additional insight into the biological effects of sotagliflozin, Lexicon's first-in-class dual SGLT1 and SGLT2 inhibitor. The investigator-initiated studies, funded by Lexicon and conducted by independent academic investigators, demonstrated favorable effects of sotagliflozin on key pathways involved in hypertrophic cardiomyopathy (HCM) and thrombotic cardiovascular events.